Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
zevalin | Biologic Licensing Application | 2023-04-25 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
b-cell lymphoma | — | D016393 | — |
follicular lymphoma | — | D008224 | C82 |
Expiration | Code | ||
---|---|---|---|
ibritumomab tiuxetan, Zevalin, Acrotech Biopharma Inc. | |||
2109-02-19 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | 6 | 19 | 6 | 1 | 6 | 35 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 14 | 3 | — | — | 18 |
Follicular lymphoma | D008224 | — | C82 | 3 | 10 | 5 | — | 1 | 17 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 11 | 26 | — | — | 3 | 34 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 2 | 9 | — | — | — | 10 |
Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 4 | 5 | — | — | — | 6 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 3 | — | — | 1 | 5 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 3 | 4 | — | — | — | 5 |
B-cell lymphoma | D016393 | — | — | 2 | 3 | — | — | — | 4 |
Leukemia | D007938 | — | C95 | 1 | 3 | — | — | — | 3 |
Burkitt lymphoma | D002051 | — | C83.7 | 1 | 3 | — | — | — | 3 |
Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | 1 | 2 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Ibritumomab tiuxetan |
INN | ibritumomab tiuxetan |
Description | Immunoglobulin G1, anti-(human CD20 (antigen)) (mouse monoclonal IDECÂY2B8 71-chain), disulfide with mouse monoclonal IDEC-Y2B8 x-chain, dimer, iV-[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl) propyl]ÂiV-[2-[bis(carboxymethyl) amino]propyl]glycine conjugate |
Classification | Antibody |
Drug class | monoclonal antibodies; chelating agents |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 206181-63-7 |
RxCUI | 262323 |
ChEMBL ID | CHEMBL1201606 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00078 |
UNII ID | 4Q52C550XK (ChemIDplus, GSRS) |